

Neurotech Solutions Secures funding to Fuel Aggressive Growth of its ADHD screening and diagnosis business in China.

31.01.2018

Neurotech solutions (NTS), a leading provider of software-based ADHD screening and diagnostic tests is expanding its activity into the Chinese market. The company recently secured significant investment for sales growth in China from the Guangzhou-Israel Biomedical Fund (GIBF) . The transaction provides significant growth capital that will enable the company to grow into a \$1B market opportunity, involving 211M School children.

"This business expansion is extremely important for Neurotech solutions, our customers, our employees and our investors", said **Ohad Lavi**, Chief Executive Officer of Neurotech Solutions. "Neurotech is in a very strong position to build a unique eco-system in China that will significantly advance the quality of ADHD diagnosis and especially in areas of low accessibility to high quality diagnosis and treatment. Our solutions are built on years of academic research resulting in a sophisticated AI based system that has market disruptive potential. We are anticipating a strong market adoption of our technology in China".

"ADHD is a relatively common neurodevelopmental disorder that creates significant social and educational impairment for children and families living in China and for the health and education systems that serve them", said *Prof. Sonuga-Barke*, Professor of Developmental Psychology, Psychiatry and Neuroscience at the Institute of Psychology, Psychiatry and Neuroscience, Kings College London and Editor in Chief of the Journal of Child Psychology and Psychiatry, "There are effective treatments for ADHD. However, getting the treatment to the right children depends on accurate identification/screening and eventual diagnosis. This is a major challenge in the context of the Chinese educational and clinical systems given the vast numbers of children to assess and the resource constraints operating. MOXO is an established evidence-based computer-delivered automated assessment tool that provides an objective assessment of the different components of ADHD – hyperactivity, inattention and impulsivity. When used in schools, together with other, more subjective, measures, such as ADHD rating scales, it provides a quick, efficient and cost effective way to screen children for ADHD. When used in the clinic it provides important additional diagnostic information that can help pinpoint the exact nature of the ADHD child's deficits – be they especially in the attentional or the impulsivity domains – this can be important in targeting treatments more effectively but also in monitoring change following treatment. In this way Moxo can add considerable value to the management of ADHD and related problems in China".

Added Prof. Shlomo Noy, chief of the integrative medical center and the rehabilitation hospital in Sheba and senior partner at GIBF. "ADHD has become a major problem on both the medical and the social aspects for children and their families. It is also a debatable health policy issue on a national level all over the world and moreover in China due to the one child policy. Neurotech gives us a much more powerful and accurate solution to this challenge based on simulation, compared to the current solutions which are based on subjective questionnaires that might lead to unnecessary medications intake. This artificial intelligence tool will enable the therapists to lead a personalized therapy in complex situations".

The new company, "Guangzhou Ruiluo Technology development Ltd", (广州瑞络科技开发有限公司), will be partly owned by the local Guangzhou government, and is scheduled to start local operations soon.

About Neurotech Solutions (NTS)

Neurotech Solutions Ltd (NTS), is an e-health, Israel based company at the forefront of applying on-line, cloud-based, clinically validated products in the field of attention. The company's' mission is to help people who struggle with ADHD improve their quality of life and fulfil their potential. To that end, the company transforms clinical knowledge, into insightful Screening & Diagnosis tools, while continuously developing innovative Intervention programs and efficient Monitoring systems.

About Guangzhou-Israel Biotech Fund (GIBF)

The GIBF Group is an Israeli group, headed by Dr. Shuki Gleitman, a previous Chief Scientist of the State of Israel, which has a major collaboration with the Guangzhou Government. The GIBF Group controls and manages the Guangzhou-Israel Sino Bio-industry Investment Fund - a ¥ 606 million fund dedicated to investments in Israeli biomedical technologies; the Guangzhou Yisheng Investment Management Company - the first ever R&D incubator in China that operates according to the successful Israeli incubation model; and the Guangzhou Innovation Office in Tel-Aviv - the official representative of the Government of Guangzhou in Israel.